PERSON
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024
Headlight: PillPack Co-Founder Backs Mental Health Startup’s $18M Funding in Transformative Care Mission
PillPack, Amazona, Clinician, Practice Experience
Scion Life Sciences Emerges with $310M Fund to Nurture Innovative Biotechnology Startups
Scion, Scion Life Sciences, Investments, Mature
Jazz Pharmaceuticals Expands Oncology Pipeline with Redx’s KRAS Inhibitor Program
Kirsten murine sarcoma virus, Jazz, Redx, Inhibitor
2 former Apple Tree investors roll toward new biotech-focused fund launching with $310M
Scion, launch, Scion Life Sciences
I-Mab Transitions to US-focused Biotech with Divestment of Chinese Operations
I-Mab’s, United States, I-Mab, Surgical aspects
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal
GSK details Blenreps PhIII combo winas it hopes to stage a turnaround in multiple myeloma
Multiple Myeloma, Blenrep, turnaround, GSK’s, Progression-Free Survival, Combined
4DMT’s Gene Therapy Reduces Eylea Injections, Advancing Plans for Phase 3 Trial in Wet AMD
Glycogen storage disease type II, 4DMT, gene therapy, Trial Phase